百利天恒(02615)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

02615 百利天恒

待上市 03-20 16:00:00

0.000

+0.000

--

最高0.000	最低0.000	成交量0.00
今开0.000	昨收0.000	日振幅0.00%
总市值0.00	流通市值0.00	总股本4.22亿
成交额0.00	换手率0.00%	流通股本4.22亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"02615","market":"HK","secType":"STK","nameCN":"百利天恒","latestPrice":0,"timestamp":1773993600000,"preClose":0,"halted":7,"volume":0,"delay":0,"floatShares":421508117,"shares":421508117,"eps":0,"marketStatus":"待上市","change":0,"latestTime":"03-20 16:00:00","open":0,"high":0,"low":0,"amount":0,"amplitude":0,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-2.204,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":4102450200000},"marketStatusCode":8,"adr":0,"listingDate":4102416000000,"exchange":"SEHK","adjPreClose":0,"openAndCloseTimeList":[[1773970200000,1773979200000],[1773982800000,1773993600000]],"volumeRatio":0,"ipoDetail":{"name":"百利天恒","exchange":"SEHK","listingDate":"2100-01-01","sharesOutstanding":421508117,"sharesFloat":421508117,"offerAmount":8634300,"priceRange":"347.500 - 389.000","market":"HK","openProspectusDate":"2025-11-07","openProspectusUrl":"https://www1.hkexnews.hk/listedco/listconews/sehk/2025/1107/2025110700014_c.pdf","purchaseBeginDate":"2025-11-07","purchaseEndDate":"2025-11-12","winningDate":"2025-11-14","currency":"HKD","minPurchaseQuantity":100,"peRate":39.25,"use":"1、约60.0%或1,810.5百万港元将用于拨付于中国内地以外地区的生物候选药物的研发活动；\n2、约30.0%或905.2百万港元将用于建立全球供应链，主要为在中国内地以外地区的生物候选药物的新生产设施的建设或潜在收购机会提供资金；\n3、约10.0%或301.7百万港元将用于拨付在中国内地以外业务的营运资金及其他一般公司用途。","industryId":"204005","industryName":"医疗保健","business":"公司是一家具备早期研发、临床开发、生产及商业化能力的综合医疗企业集团。","subscribed":19.93,"marketCap":146474000000,"minimumCapital":39292.31,"overAllotment":false,"lotSize":100,"issueOpenRate":0.1,"subscribeGear":"100,200,300,400,500,600,700,800,900,1000,1500,2000,2500,3000,3500,4000,4500,5000,6000,7000,8000,9000,10000,15000,20000,25000,30000,35000,40000,45000,50000,60000,70000,80000,90000,100000,150000,200000,300000,431700"},"greyMarketDetail":{"greyDate":"2099-12-31","greyDateTimestamp":4102329600000,"greyOpeningTime":4102388100000,"greyClosingTime":4102396200000,"showGreyQuote":false,"openProspectusDate":"2025-11-07","listingDate":"2100-01-01"},"lotSize":100,"spreadScale":0,"tradeCurrency":"HKD","astockBrief":{"symbol":"688506","market":"SH","secType":"STK","nameCN":"百利天恒","latestPrice":271.48,"timestamp":1773990000000,"preClose":269.38,"halted":0,"volume":1595000,"delay":0,"premium":"-100.00"}},"requestUrl":"/m/hq/s/02615","defaultTab":"news","newsList":[{"id":"2621371933","title":"百利天恒(688506.SH)创新药BL-ARC002注射液获临床试验批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2621371933","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2621371933?lang=zh_cn&edition=full","pubTime":"2026-03-22 15:41","pubTimestamp":1774165288,"startTime":"0","endTime":"0","summary":"智通财经APP讯，百利天恒(688506.SH)公告，公司近日收到国家药品监督管理局(NMPA)正式批准签发的《药物临床试验批准通知书》，公司自主研发的创新药BL-ARC002注射液的药物临床试验获得批准。公告称，BL-ARC002通过抗体介导的精准靶向递送技术及放射性核素强大的肿瘤杀伤能力，与传统放射性核素偶联药物相比，具有更强的靶点特异性、更高的肿瘤富集性，并有望展现出更好的抗耐药性。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1417046.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02615","BL","06978","LU0757428866.USD","BK0239","BK1161","BK4023","BK1574","LU1815336091.USD","688506","159992","91194"],"gpt_icon":0},{"id":"2621795056","title":"每周股票复盘：百利天恒（688506）2.88%限售股将上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2621795056","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2621795056?lang=zh_cn&edition=full","pubTime":"2026-03-22 01:29","pubTimestamp":1774114150,"startTime":"0","endTime":"0","summary":"截至2026年3月20日收盘，百利天恒报收于271.48元，较上周的257.33元上涨5.5%。本周关注点公司公告汇总：百利天恒2.88%限售股将于2026年3月25日上市流通公司公告汇总：本次限售股涉及中欧基金、易方达基金等18名机构投资者公司公告汇总：限售股锁定期6个月，保荐机构中信证券无异议公司公告汇总百利天恒向特定对象发行的11,873,817股限售股将于2026年3月25日上市流通，占公司总股本的2.88%。中信证券作为保荐人，对本次限售股上市流通无异议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026032200000173.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","02615","688506","91194"],"gpt_icon":0},{"id":"2620624216","title":"百利天恒披露iza-bren联合免疫一线治疗广泛期小细胞肺癌研究数据","url":"https://stock-news.laohu8.com/highlight/detail?id=2620624216","media":"证券日报","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2620624216?lang=zh_cn&edition=full","pubTime":"2026-03-19 13:35","pubTimestamp":1773898522,"startTime":"0","endTime":"0","summary":"百利天恒披露iza-bren联合免疫一线治疗广泛期小细胞肺癌研究数据","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202603193677222420.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["688506","91194","02615","BK0239"],"gpt_icon":0},{"id":"2620428282","title":"百利天恒：1187.38万股限售股3月25日解禁","url":"https://stock-news.laohu8.com/highlight/detail?id=2620428282","media":"南方财经网","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2620428282?lang=zh_cn&edition=full","pubTime":"2026-03-17 17:50","pubTimestamp":1773741038,"startTime":"0","endTime":"0","summary":"南财智讯3月17日电，百利天恒公告，公司向特定对象发行的限售股将于2026年3月25日上市流通，本次解禁股份数量为1187.38万股，占公司总股本的2.88%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202603173674678418.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["688506","02615","BK0239","91194"],"gpt_icon":0},{"id":"2619178242","title":"每周股票复盘：百利天恒（688506）完成1.99亿元股份回购","url":"https://stock-news.laohu8.com/highlight/detail?id=2619178242","media":"证券之星","labels":["shareholding","buyback"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2619178242?lang=zh_cn&edition=full","pubTime":"2026-03-15 03:09","pubTimestamp":1773515351,"startTime":"0","endTime":"0","summary":"截至2026年3月13日收盘，百利天恒报收于257.33元，较上周的258.5元下跌0.45%。本周，百利天恒3月10日盘中最高价报285.0元。本周关注点公司公告汇总：百利天恒已完成约2亿元股份回购，累计回购695,862股。公司公告汇总四川百利天恒药业股份有限公司于2025年12月30日召开董事会，审议通过回购股份方案，拟以集中竞价交易方式回购公司股份，用于员工持股计划或股权激励。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026031500000947.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding,buyback","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["02615","91194","BK0239","688506"],"gpt_icon":0},{"id":"2618139911","title":"百利天恒回购70万股 金额2亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2618139911","media":"财中社","labels":["shareholding","buyback"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2618139911?lang=zh_cn&edition=full","pubTime":"2026-03-12 19:25","pubTimestamp":1773314707,"startTime":"0","endTime":"0","summary":"百利天恒（688506）发布公告，截至2026年3月12日，公司已回购70万股，占总股本的0.17%，实际回购金额为2亿元，回购价格区间为243.44元/股至345.24元/股。2025年前三季度，百利天恒实现收入20.66亿元，归母净利润-4.95亿元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202603123670321391.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,buyback","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["02615","91194","BK0239","688506"],"gpt_icon":0},{"id":"2618188071","title":"华夏时报：百利天恒业绩变脸 从年赚37亿到年亏10.5亿","url":"https://stock-news.laohu8.com/highlight/detail?id=2618188071","media":"中金财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2618188071?lang=zh_cn&edition=full","pubTime":"2026-03-12 14:42","pubTimestamp":1773297724,"startTime":"0","endTime":"0","summary":"中国经济网北京3月12日讯 华夏时报9日报道《一年净赚37亿元到巨亏10亿元！百利天恒业绩“变脸”，创新药烧钱模式能撑多久？》显示，百利天恒 于2026年2月28日发布2025年年度业绩快报公告。公告显示，公司在2025年实现营业总收入25.2亿元，较上年同期的58.23亿元减少56.72%；归属于母公司所有者的净利润为-10.51亿元，较上年同期的37.08亿元大幅转亏，同比减少128.34%。2025年仅前三季度，百利天恒研发费用就高达17.72亿元，同比增长90.23%。","market":"sh","thumbnail":" http://caiji.3g.cnfol.com/colect/202603/12/20260312157276.png","type":0,"news_type":0,"thumbnails":[" http://caiji.3g.cnfol.com/colect/202603/12/20260312157276.png"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushijujiao/20260312/32062948.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["02615","688506","91194","BK0239"],"gpt_icon":0},{"id":"2618646015","title":"聚焦四川上市公司 | 42家上市川企发布2025年业绩预告智明达预增4倍领跑，百利天恒由盈转亏","url":"https://stock-news.laohu8.com/highlight/detail?id=2618646015","media":"金融投资网","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2618646015?lang=zh_cn&edition=full","pubTime":"2026-03-09 16:36","pubTimestamp":1773045375,"startTime":"0","endTime":"0","summary":"A股上市公司2025年业绩快报还在持续披露中，截至目前，四川省内已有42家上市公司发布了2025年业绩快报。就已发布业绩快报的四川上市公司的情况来看，其业绩呈现喜忧参半的态势。Wind统计数据显示，在已披露业绩快报的四川上市公司中，有21家全年业绩实现同比增长，占披露总数的一半，其余21家的业绩则出现了不同程度的下滑。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202603093666101871.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK0239","688636","BK0214","02615","688506","91194"],"gpt_icon":0},{"id":"2618646523","title":"一年净赚37亿元到巨亏10亿元！百利天恒业绩“变脸”，创新药烧钱模式能撑多久？","url":"https://stock-news.laohu8.com/highlight/detail?id=2618646523","media":"华夏时报网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2618646523?lang=zh_cn&edition=full","pubTime":"2026-03-09 16:23","pubTimestamp":1773044603,"startTime":"0","endTime":"0","summary":"四川百利天恒药业股份有限公司（下称“百利天恒”，股票代码：688506.SH）于2026年2月28日发布2025年年度业绩快报公告。公告显示，公司在2025年实现营业总收入25.2亿元，较上年同期的58.23亿元减少56.72%；归属于母公司所有者的净利润为-10.51亿元，较上年同期的37.08亿元大幅转亏，同比减少128.34%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202603093666088735.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202603093666088735.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["02615","06978","159992","BK0239","BK1161","688506","91194","BK1574"],"gpt_icon":0},{"id":"2617517185","title":"百利天恒（688506）披露注射用BL-M11D1获临床试验批准通知书，3月5日股价上涨4.84%","url":"https://stock-news.laohu8.com/highlight/detail?id=2617517185","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2617517185?lang=zh_cn&edition=full","pubTime":"2026-03-05 17:20","pubTimestamp":1772702439,"startTime":"0","endTime":"0","summary":"截至2026年3月5日收盘，百利天恒报收于254.87元，较前一交易日上涨4.84%，最新总市值为1052.29亿元。四川百利天恒药业股份有限公司于2026年3月5日发布自愿披露公告，称公司近日收到国家药品监督管理局签发的《药物临床试验批准通知书》，同意公司自主研发的创新生物药注射用BL-M11D1开展用于治疗复发或难治性骨髓增生异常综合征的临床试验。目前BL-M11D1在国内进行Ib期临床试验，在美国进行I期临床试验，适应症为复发或难治性急性髓系白血病。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026030500027855.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["02615","BK0239","91194","688506"],"gpt_icon":0},{"id":"2616318725","title":"百利天恒：自研ADC药物注射用BL-M11D1获批临床","url":"https://stock-news.laohu8.com/highlight/detail?id=2616318725","media":"财中社","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2616318725?lang=zh_cn&edition=full","pubTime":"2026-03-04 18:46","pubTimestamp":1772621169,"startTime":"0","endTime":"0","summary":"3月4日，百利天恒（688506）发布公告，公司自主研发的创新生物药注射用BL-M11D1（CD33-ADC）的药物临床试验获得批准。BL-M11D1是与iza-bren出自同一技术平台、与iza-bren共享同一“连接子+毒素”平台的靶向CD33的ADC药物。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202603043661878918.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["91194","BK4080","BK4231","LU1815336091.USD","BK0239","02615","LU0757428866.USD","BL","688506","BK4023","ADC"],"gpt_icon":0},{"id":"2616070233","title":"真金白银力挺硬科技，19家科创板公司公告回购进展","url":"https://stock-news.laohu8.com/highlight/detail?id=2616070233","media":"界面","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2616070233?lang=zh_cn&edition=full","pubTime":"2026-03-04 11:27","pubTimestamp":1772594876,"startTime":"0","endTime":"0","summary":"3月3日晚间，包括澜起科技、百利天恒等19家科创板公司公告回购进展，通过加大回购力度增强投资者回报。同时，多家科创板公司再融资消息不断，路维光电向特定对象发行A股股票申请获上交所受理，先锋精科公告拟发行可转债募资不超过7.5亿元。（界面新闻记者 孙艺真)","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260304112756a6a033c5&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260304112756a6a033c5&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1163","06809","02615"],"gpt_icon":0},{"id":"2616834626","title":"百利天恒累计回购54万股 金额1.61亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2616834626","media":"财中社","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2616834626?lang=zh_cn&edition=full","pubTime":"2026-03-03 18:32","pubTimestamp":1772533937,"startTime":"0","endTime":"0","summary":"3月3日，百利天恒（688506）发布公告，截至2026年2月28日，公司累计回购54万股，占总股本的0.13%，回购资金总额为1.61亿元，实际回购价格区间为267.36元/股至345.24元/股。2025年前三季度，百利天恒实现收入20.66亿元，归母净利润-4.95亿元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202603033660497540.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK0239","91194","688506","02615"],"gpt_icon":0},{"id":"2614799835","title":"百利天恒：2025年归母净亏损10.51亿元 同比盈转亏","url":"https://stock-news.laohu8.com/highlight/detail?id=2614799835","media":"每日经济新闻","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2614799835?lang=zh_cn&edition=full","pubTime":"2026-02-27 17:19","pubTimestamp":1772183985,"startTime":"0","endTime":"0","summary":"每经AI快讯，2月27日，百利天恒(688506.SH)发布2025年年度业绩快报，营业总收入为25.20亿元，同比减少56.72%；归属于母公司所有者的净利润为-10.51亿元，同比盈转亏。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202602273656760446.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202602273656760446.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["688506","02615","91194","BK0239"],"gpt_icon":0},{"id":"2614083875","title":"首度全年盈利的百济神州，与川股百利天恒有一个共同点：都被这些公募基金重仓","url":"https://stock-news.laohu8.com/highlight/detail?id=2614083875","media":"金融投资报","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2614083875?lang=zh_cn&edition=full","pubTime":"2026-02-27 16:51","pubTimestamp":1772182279,"startTime":"0","endTime":"0","summary":"金融投资报记者贺梦璐“盈利了，但市值却跌破3000亿元。”这或许是百济神州发布2025年度业绩快报后，留给资本市场的最大困惑。金融投资报记者注意到，当投资者将目光转向其股东名单时，一个有意思的巧合开始浮现：那些重仓百济神州的公募基金，同样也对川股百利天恒青睐有加。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202602273656715059.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["06160","ONC","LU1719994722.HKD","LU1251922891.USD","BK1161","LU1303224171.USD","LU1770034418.SGD","BK4526","BK1588","688506","BK4585","LU2328871848.SGD","BK1500","LU0307460666.USD","LU0588546209.SGD","688235","BK0239","BK1583","BK4588","LU1969619763.USD","BK4139","02615","91194"],"gpt_icon":0},{"id":"2614091923","title":"盈喜预告接连发布：BD成估值新锚，药企加速跨越生死线","url":"https://stock-news.laohu8.com/highlight/detail?id=2614091923","media":"21世纪经济报道","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2614091923?lang=zh_cn&edition=full","pubTime":"2026-02-26 14:29","pubTimestamp":1772087394,"startTime":"0","endTime":"0","summary":"2月25日，先声药业发布盈喜预告。预告显示，2025财政年度公司预计录得收入约人民币77亿至78亿元，同比增长16.0%至17.6%；而归属于公司权益股东的利润更是有望达到人民币13亿至14亿元，同比增幅高达80.1%至93.9%。在医药行业整体仍在调整期中艰难跋涉的背景下，这份接近翻倍的利润增长答卷显得尤为耀眼。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202602263655228925.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202602263655228925.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1583","02096","BK1574","06978","BMS","BK1161","02615","BK1191"],"gpt_icon":0},{"id":"2613713953","title":"百利天恒双抗ADC达到Ⅲ期临床试验主要终点 为三阴性乳腺癌治疗提供新选项","url":"https://stock-news.laohu8.com/highlight/detail?id=2613713953","media":"每日经济新闻","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2613713953?lang=zh_cn&edition=full","pubTime":"2026-02-24 19:39","pubTimestamp":1771933190,"startTime":"0","endTime":"0","summary":"2月23日，百利天恒（SH688506，股价289.59元，市值1195.6亿元）宣布其自主研发的全球首创EGFR×HER3双抗ADC药物（抗体偶联药物）iza-bren，在针对局部晚期或转移性三阴性乳腺癌（TNBC）的Ⅲ期临床试验中取得突破。期中分析数据显示，该药物显著延长了患者的无进展生存期（PFS）和总生存期（OS），达到双主要终点。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202602243652920641.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202602243652920641.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["91194","688506","BK0239","BK4080","ADC","02615","BK4231"],"gpt_icon":0},{"id":"2614720250","title":"吉利德78亿美元溢价收购Arcellx；GSK与前沿生物达成超10亿美元授权；百利天恒乳腺癌III期临床达双主要终点","url":"https://stock-news.laohu8.com/highlight/detail?id=2614720250","media":"药财社","labels":["corporation","merge"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2614720250?lang=zh_cn&edition=full","pubTime":"2026-02-24 19:04","pubTimestamp":1771931050,"startTime":"0","endTime":"0","summary":"交易已获双方董事会批准，预计2026 年第二季度完成，吉利德目前已持有 Arcellx11.5% 流通股，将通过全资子公司要约收购剩余股份。2GSK与前沿生物达成超10亿美元授权近日，前沿生物与GSK正式达成一项独家授权许可协议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260224202521a719eeae&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260224202521a719eeae&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,merge","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02615","91194"],"gpt_icon":0},{"id":"2613820071","title":"百利天恒(688506.SH)：iza-bren(EGFR×HER3双抗ADC)用于局部晚期或转移性三阴乳腺癌III期临试期中分析达到主要终点","url":"https://stock-news.laohu8.com/highlight/detail?id=2613820071","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2613820071?lang=zh_cn&edition=full","pubTime":"2026-02-23 16:56","pubTimestamp":1771836964,"startTime":"0","endTime":"0","summary":"智通财经APP讯，百利天恒 披露公告，关于iza-bren用于局部晚期或转移性三阴乳腺癌III期临床试验的期中分析达到主要终点的事项，该III期临床研究独立数据监查委员会，在预设的期中分析中，建议：“基于现有的分析结果，与监管沟通提前申报，同时继续对受试者进行随访”。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1406323.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4134","91194","BK4231","02615","BK4080","ADC","III","688506","BK0239"],"gpt_icon":0},{"id":"2611014356","title":"每周股票复盘：百利天恒（688506）董秘离任由张苏娅代行职责","url":"https://stock-news.laohu8.com/highlight/detail?id=2611014356","media":"证券之星","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2611014356?lang=zh_cn&edition=full","pubTime":"2026-02-15 01:15","pubTimestamp":1771089314,"startTime":"0","endTime":"0","summary":"截至2026年2月13日收盘，百利天恒报收于287.0元，较上周的281.0元上涨2.14%。本周，百利天恒2月11日盘中最高价报299.75元。本周关注点公司公告汇总：董事会秘书陈英格因个人原因离任，由张苏娅代行职责公司公告汇总四川百利天恒药业股份有限公司董事会于2026年2月13日收到董事会秘书陈英格女士的辞呈，因其个人原因申请辞去董事会秘书职务，离任后不再担任公司任何职务。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026021500000152.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["02615","BK0239","91194","688506"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.baili-pharm.com","compareEarnings":[{"period":"1week","weight":-0.0074},{"period":"1month","weight":-0.0535},{"period":"3month","weight":-0.0161},{"period":"6month","weight":-0.0478},{"period":"1year","weight":0.0437},{"period":"ytd","weight":-0.0138}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"公司是一家聚焦于全球生物医药前沿领域，立足于解决临床未被满足的需求，具备包括小分子化学药、大分子生物药及ADC药物的全系列药品研究开发能力，并拥有从中间体、原料药到制剂一体化优势的、覆盖“研发—生产—营销”完整全生命周期商业化运营能力的生物医药企业。公司拥有两大业务板块,分别为创新生物药业务和化药制剂、中成药制剂业务板块。公司主要产品:丙泊酚乳状注射液、丙泊酚中/长链脂肪乳注射液、吸入用七氟烷、结构脂肪乳注射液(C6~24)、黄芪颗粒、盐酸胍法辛缓释片、葡萄糖电解质泡腾片。","exchange":"SEHK","name":"百利天恒","nameEN":"BIOKIN"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.37.0","shortVersion":"4.37.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"百利天恒(02615)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供百利天恒(02615)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"百利天恒,02615,百利天恒股票,百利天恒股票老虎,百利天恒股票老虎国际,百利天恒行情,百利天恒股票行情,百利天恒股价,百利天恒股市,百利天恒股票价格,百利天恒股票交易,百利天恒股票购买,百利天恒股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"百利天恒(02615)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供百利天恒(02615)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}